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What is the impact of rerouting a cancer
diagnosis from emergency presentation to
GP referral on resource use and survival?
Evidence from a population-based study
Mauro Laudicella1* , Brendan Walsh2, Elaine Burns3, Paolo Li Donni4 and Peter C. Smith5
Abstract
Background: Studies on alternative routes to diagnosis stimulated successful policy interventions reducing the
number of emergency diagnoses and associated mortality risk. A dearth of evidence on the costs of such
interventions might prevent new policies from achieving more ambitious targets.
Methods: We conducted a retrospective cohort study on the population of colorectal (88,051), breast (90,387),
prostate (96,219), and lung (97,696) cancer patients diagnosed after a GP referral or an emergency presentation and
reported in the Cancer Registry of England. Resource use and survival were compared 1 year before and 5 years after
diagnosis (3 years for lung), including the costs of GP referrals not converted into a positive diagnosis. Risk-adjusted
statistical models were used to calculate the effect of rerouting patient’ diagnoses from emergency presentation
to GP referral.
Results: Rerouting a cancer diagnosis results in a relatively small additional costs to the National Health System
against additional years of life saved to the patient. The cost per year of life saved is £6456 in colorectal, £1057 in
breast, −£662 in prostate (savings), and £819 in lung cancer. Reducing the overall prevalence of emergency presentations
to the level achieved by the 20% of Clinical Commissioning Groups with the lowest prevalence would result
in £11,481,948 against 1863 years of life saved for Colorectal, £847,750 against 889 years for breast, −£943,434
(cost savings) against 1195 years for prostate, and £609,938 against 1011 years for lung cancer.
Conclusion: Redirecting diagnoses from emergency presentation to GP referral appears an achievable target
that can produce large benefits to patients against modest additional costs to the National Health System.
Keywords: Route to diagnosis, Emergency, Primary care, Hospital costs, Survival, Early diagnosis
Background
Patients diagnosed after an emergency presentation (EP)
experience considerably poorer short term survival than
following alternative routes to diagnosis (RTD), such as
a general practitioner (GP) referral [1–3]. One in five
cancers diagnosed in England occur after an EP [1, 4, 5].
A late stage diagnosis can be caused by delays in patient
presentation, delays in primary care, delays between pri-
mary and secondary care, and delays in secondary care
[6]. Although EP are more likely to be associated with
atypical symptoms, opportunities for an earlier diagnosis
via alternative routes can be found in a substantial share
of EP patients [7]. Reducing the number of diagnoses
occurring after an EP could result in a considerable im-
provement in short term cancer survival reducing the
gap between England and similar high income countries.
Studies on the health outcomes associated with alter-
native routes to diagnosis have stimulated a number of
policy interventions aiming at reducing the number of
patients diagnosed via the emergency routes. Initiatives
such as the National Awareness and Early Diagnosis Ini-
tiative (NAEDI) and GP referral guidance issued by the
National Institute of Health and Care Excellence (NICE)
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promote the earlier diagnosis of cancer through increas-
ing the public awareness of symptoms; and increasing
diagnoses through primary care [8]. There is, however, a
dearth of evidence on the costs of such interventions
and the long term consequences for the use of health
resources. This might prevent health policies from
achieving more ambitious targets in improving patient
safety and cancer survival.
The objective of our study is to estimate the effect of
rerouting a cancer diagnosis from EP to GP referrals on
the utilisation of health care resources. Our analysis
identifies cancer sites with scope for achieving better
survival outcomes with a relatively small additional in-
vestment of resources. We also disentangled the effect
on resource use that is driven by differences in survivals,
i.e. patients living longer after their diagnosis, from the
effect that is driven by differences in intensity of re-
source use, i.e. patients accessing more expensive treat-
ments after their diagnosis. In the short term, EP
patients are likely to use more resources for their treat-
ment than patients diagnosed via a GP referral. However,
the former are also likely to experience shorter survival
times and have fewer opportunities to use health
resources in the long term. Disentangling the intensity
effect from the survival effect may be useful to assess
the impact of policy interventions. Cost savings from re-
ducing the intensity of resource use could be off-set by
additional costs from extending the life of the patient.
Therefore, a policy intervention could have little impact
on total cost and yet achieve a desirable reallocation of
resource use from intensity to survival.
Methods
We performed an observational study on the population
of patients with colorectal, breast, prostate and lung can-
cer. Patient-level data from each cohort are analysed
separately using statistical models that allow for compar-
ing utilisation of care in patients diagnosed via an EP
and a GP after controlling for differences in patient
characteristics. Patients are followed retrospectively
1 year before and up to 5 years after the diagnosis. Re-
source use before the diagnosis is likely to be driven by
the cancer condition especially in patients with a late
stage diagnosis who are more likely to follow the emer-
gency route [1]. Therefore, including resource use before
the diagnosis allows us to make a balanced comparison
of costs across different routes. We also included the
costs of non-converted cases (i.e. negative diagnosis) in
the analysis. In order to achieve one extra diagnosis via a
GP referral, a large number of patients with suspected
cancer has to be referred for diagnostic tests. Therefore,
the cost of the negative diagnoses should be added to
the cost of the positive.
Data
Our analysis uses a linked dataset including patient-level
information from the National Cancer Data Repository
(NCDR) matched with data on utilisation of inpatient
and outpatient services from the Hospital Episodes Sta-
tistics (HES) and their costs from the National Schedules
of Reference Costs (NSRC). NDCR matched to HES data
were provided by the National Cancer Registration and
Analysis Service (NCRAS) of Public Health England
(PHE). The NCDR provides information on the charac-
teristics of the patients, including age, tumour site, in-
come deprivation in the area of residence, date of
diagnosis, and date of death. The algorithm developed
by Elliss-Brookes et al. [1] identifies patients diagnosed
after an emergency presentation and after a GP referral
in the dataset. We combined non-urgent and urgent
2 week wait (TWW) referrals in the analysis and referred
to this route as GP/TWW referral throughout.
The HES database records information on patients’
utilisation of inpatient and outpatient hospital care for
all National Health Service (NHS) patients in England,
including information on principal and secondary diag-
noses, operations performed, and method of admission.
The NSRC includes information on the cost of inpatient
and outpatient services accessed by NHS patients. Cost
data are disaggregated at the level of Healthcare Re-
source Group (HRG) making special adjustments for pa-
tients’ type of admission, length of stay, and access to
special services. A more detailed description of the pro-
cedure followed to match HES with NSRC data has been
provided elsewhere [9]. The use of HES and NCDR for
estimating inpatient costs has been validated in a previ-
ous study [10].
NCRAS provided estimates of the conversion rates
from their analysis of the TWW referral data for the fis-
cal year 2014/15. Conversion rates are defined as the
share of positive cancer diagnoses out of the total TWW
referrals made in the year. Costs of non-conversion cases
are obtained from a report study by Frontier Economics
for the Department of Health [11].
The share of diagnoses occurring after an EP in the
Clinical Commissioning Groups (CCGs) of England was
calculated by using Cancer Registry data on patients di-
agnosed between January 2010 and December 2013.
Patients
We included individuals aged over 18 with a diagnosis
of colorectal cancer (ICD-10 code: C18, C19, C20),
breast cancer (C50), prostate cancer (C61), or lung
cancer (C33, C34) occurred after an EP or a GP/TWW
referral and was reported in the cancer registries of
England between March 2006 and April 2009. Cancer
diagnoses occurring before 2006 were excluded as
information on route to diagnosis is not available. We
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excluded individuals with a previous diagnosis of cancer,
males with breast cancer, and patients reported to have
died with improper death certificate (DCO) registrations.
Patients were followed up 1 year before and up to
5 years after their diagnosis until March 2010. We ex-
cluded patients diagnosed between April 2009 and
March 2010 to allow for a minimum of 12 months
follow-up for all patients.
Endpoints
The primary outcome of this study is the utilisation of
health resources, which was defined in terms of the cost
of the care provided to patients by NHS hospitals. The
terms “resource use” and “costs” are used interchange-
ably throughout the analysis. Resource use was mea-
sured at 2010 prices. Secondary outcome measures are
1 year and 5 years survival after diagnosis.
Control variables
The statistical models used in the analysis include a
number of control variables to allow for differences in
patient characteristics that might influence resource use
and survival outcomes between the EP and GP/TWW
referral routes to diagnosis. We controlled for patients’
age at diagnosis, gender, and a set of comorbidity indica-
tors based on the Charlson index, including: acute myo-
cardial infarction, congestive heart failure, peripheral
vascular disease, cerebrovascular disease, dementia,
chronic obstructive pulmonary disease, rheumatoid dis-
ease, peptic ulcer, liver disease, diabetes, and renal dis-
ease. We also controlled for number of co-diagnoses
reported during the first inpatient stay, a binary indica-
tor if surgery performed in the first 12 months from
diagnosis, and geographical region of residence, and in-
come deprivation in the patient small area of residence
(i.e., Lower Layer Super Output Area with average popu-
lation of 1500 units).
Cancer staging was not used as a control variable as
we aim to capture the impact of late and early diagnosis
via the EP and the GP/TWW referral route.
Statistical analysis
Estimating patient-level costs is challenging due to right
censoring, and accelerated cost accumulation at the
point of diagnosis and at the end of life. Cancer patients
enter our study throughout the time period as they are
diagnosed, between 2006 and 2009; hence resource use
cannot be measured for the full 5 years for all patients,
resulting in censored observations. The cost distribution
is characterised by a U-shape with spikes in resource use
at the time of diagnosis and at the end of life, which
complicate the correct estimation of the effect of routes
to diagnosis on costs [9, 12, 13]. Routes to diagnosis are
likely to have an impact on costs through two distinct
channels: by accelerating the use of resources (intensity
effect) and by extending the life of the patient (survival
effect). EP patients are more likely to use expensive re-
sources over a short period of time after their diagnosis,
while GP/TWW patients are more likely to use less ex-
pensive resources over a long period of time as they are
more likely to survive cancer.
We estimated the effect of route to diagnosis on costs
using the Basu-Manning (BM) estimator that allows for
the comparison of retrospective patterns of utilisation of
care in patients diagnosed after an EP and a GP referral
addressing all the issues described above [14]. The BM-
estimator consists in a three-part statistical model: a
Probit model estimating differences in the probability
of surviving and two Generalised Linear Models
(GLM) estimating cost differences in every interval of
time. The BM estimator assumes random censoring,
which is a standard assumption in a wide class of
survival models for time to event studies [14]. A de-
tailed description of the BM estimator is included in
a technical appendix file [see Additional file 1].
Survival
Survival outcomes were examined by using continuous
Weibull accelerated failure time models, which allows
for estimating the survival outcomes associated with
alternative routes after controlling for differences in
patient characteristics described in the Control Variables
section. In sensitivity analysis we found very similar
predictions when using semi-parametric Cox regression
models.
Results
In total, 88,051 colorectal, 90,387 breast, 96,219 prostate,
and 97,696 lung cancer patients were included. Table 1
shows the characteristics of patients in our study popu-
lation by tumour sites. EP patients are older, have a
higher morbidities and mortality risk as measured by the
Weighted Charlson Index, and are more likely to come
from an income deprived area across all tumour sites ex-
amined than the GP/TWW referrals. EP patients are less
likely to receive surgery within 12 months of diagnosis
than GP/TWW patients.
Figure 1 plots the average effect on resource use of
rerouting a patient from EP to GP/TWW referral.
Figure 1 includes inpatient and outpatient costs only,
and is cumulated by month from diagnosis to 5 year
later (3 years for lung). Non-conversion costs and pre-
diagnosis costs are considered in a separate analysis.
Estimates are obtained from the BM estimator after
controlling for patient characteristics described in the
Control Variables section. Estimates can be interpreted
as the increment (or reduction) in the use of inpatient
and outpatient care associated with moving a patient
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from EP (the baseline) to GP/TWW referral. The effect
plotted in Fig. 1 is decomposed in two parts: a part
driven by differences in intensity of resource use and a
part driven by differences in survivals between patients
in the EP and GP/TWW route.
Rerouting patients from EP to GP/TWW referral results
in a gradual increment in costs over 6 years due to better
patient survival in all cancer cohorts, i.e. GP/TWW pa-
tients survive longer and have more opportunities to use
resources in the long term. The rapid drop in costs in the
first year from diagnoses is due to a reduction in intensity
of resource use in all cohorts, i.e. GP/TWW patients con-
sume less expensive resources per unit of time. Savings
from the intensity effect gradually cancelled out after
5 years as the survival effect catches up with the intensity
effect over time.
Table 2 shows the complete results of the cost analysis,
including costs due to intensity of resource use, costs
Table 1 Study population descriptive statistics
Tumour Route to
diagnosis
Number Age Female IMD Income
Deprivation (*)
Surgery within
12 Months (**)
Weighted Charlson
Index
Surviving up to
12 Months
Colorectal Emergency 27,729 73.83 45.68% 14.89% 38.16% 3.8 49.66%
GP/TWW Referral 60,322 71.09 41.22% 12.94% 63.95% 2.62 78.71%
Breast Emergency 6059 75.61 All 15.09% 15.28% 3.94 53.90%
GP/TWW Referral 84,328 63.18 All 11.88% 73.94% 3.18 94.52%
Prostate Emergency 10,350 77.89 None 14.22% 2.40% 3.7 59.15%
GP/TWW Referral 85,869 70.88 None 12.47% 9.77% 2.29 94.91%
Lung Emergency 43,026 73.81 44.15% 17.48% 1.99% 4.1 13.41%
GP/TWW Referral 54,670 70.69 43.36% 15.97% 12.66% 3.29 39.77%
(*) IMD Income deprivation measures the share of people relying on mean tested income benefits in the patient area of residence
(**) OPCS 4.3 codes for surgery: H04, H05, H06, H07, H08, H09, H10, H11, H33 Colorectal; B27, B28 Breast; M611, M614, M618, M619 Prostate; E391, E398, E399,
E441, E461, E541, E542, E543, E544, E545, E548, E549, E552, E559, E554, E574, E578, E595, T013 Lung
Fig. 1 Cumulative Differences in Costs per Patient between GP/Two Week Wait Referral and Emergency Presentation (baseline). Differences in
Costs Are Decomposed by Survival Effect (Blue line) and Intensity of Resource Use Effect (Red line). Risk-adjusted estimates are obtained from the
Basu-Manning estimator. Negative values indicate GP/TWW referral is cost saving
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due to survivals, costs of resources used in the year be-
fore the clinical diagnosis, and costs of non-conversion
cases, i.e. negative tests for patients referred for sus-
pected caner via the GP/TWW route. Total costs per
patient surviving up to 5 year are £25,716 for colorectal,
£3179 for breast, −£2013 (savings) for prostate, and
£3244 for lung cancer (3 years only). The costs per year
of life saved up to 5 years post diagnosis are £6456 in
colorectal, £1057 in breast, −£662 in prostate, and £819
in lung cancer (3 years only). It is worth noting that the
largest share of the total cost of rerouting patients is
absorbed by the non-conversion costs in all examined
cancer cohorts.
Figure 2 shows the share of EP diagnoses over the total
cancer diagnoses made via Non-EP routes across all
CCGs in England between 2010 and 2013. Figure 2 high-
lights a noticeable gap between the top performing 20%
of CCGs with the lowest share of EP diagnoses (dark
blue) and the rest of the CCGs (light blue).
Table 3 includes estimates of the potential impact of a
policy reducing the share of EP diagnoses in all CCGs to
match the average level of the top 20% of CCGs with the
lowest share. The excess of EP diagnosis are rerouted to
GP/TWW referrals. For simplicity we have assumed that
achieving the policy target has no other costs than the
direct medical costs included in Table 2, and we con-
sider the long term effects after achieving the target for
1 year only. Achieving the policy target would result in
rerouting 1303 diagnoses for colorectal, 577 for breast,
964 for prostate, and 1714 for lung in a year. They rep-
resent 3.16% of all new diagnoses for colorectal in a year,
1.04% for breast, 2.07% for prostate, and 3.69% for lung.
In order to achieve these new diagnoses from the GP/
TWW route, a much larger number of patients have to
be referred for suspected cancer: 29,977 patients for
colorectal, 7436 for breast, 6320 for prostate, and 1714
for lung. Non-conversions are the largest costs associ-
ated with the policy target as reported in Table 3. Total
costs after 5 years would amount to £11.4 million for
colorectal, £0.8 million for breast, and £0.6 million for
lung cancer (3 year costs), resulting in 1863 years of life
saved for colorectal, 889 for breast, 1195 for prostate
and 1011 for lung cancer. Colorectal cancer costs dwarf
other cancers due to the lower conversion rates and
higher costs per non-conversion case as shown in
Table 2. In contrast, achieving the policy target for pros-
tate cancer would result in − 0.9 million of cost savings
due to large intensity of care costs that would be avoided
and the relatively small additional survival costs that
would be incurred. The latter is explained by the small
difference in survival costs between the EP and the GP/
TWW route in prostate cancer relative to other cancers
as illustrated in Fig. 1 and Table 2.
Discussion
This study examined the impact on utilisation of health
resources and survival of rerouting patients’ diagnosis
from EP to GP/TWW referral. We examined a large
population of colorectal (88,051), breast (90,387),
prostate (96,219), and lung (97,696) cancer patients and
measured resource use in terms of the cost of care to
the NHS hospitals. The BM estimator is implemented to
Table 2 Effects of rerouting a cancer diagnosis from EP to GP/TWW referral
Colorectal Breast Prostate Lung
Conversion Rate (2014/15) 0.043 0.078 0.153 0.186
Costs per diagnostic test £420 £158 £157 £127
Costs per converted case (a) £9242 £1883 £874 £559
Variation in Costs 1 year pre diagnosis (b) -£546 -£497 -£887 -£534
Variation in Survival Costs 1 year post diagnosis (c) £479 £128 -£128 £669
Variation in Intensity Costs 1 year post diagnosis (d) -£1734 -£1546 -£2565 -£952
Total Costs 1 year post diagnosis (a + b + c + d) £7442 -£32 -£2706 -£258
Variation in Survival Costs 5 year post diagnosis (C) £1128 £712 £616 £907
Variation in Intensity Costs 5 year post diagnosis (D) -£1012 -£628 -£1582 -£577
Total Costs 5 year post diagnosis (a + b + C + D) £8812 £1469 -£979 £356
Variation in Probability of Surviving up to 5 year 0.359 0.512 0.408 0.149
Total Cost per patient Surviving up to 5 year £24,546 £2870 -£2399 £2388
Years of life saved up to 5 years post diagnosis (e) 1.43 1.54 1.24 0.59
Total Cost per year of life saved (e) £6162 £954 -£789 £603
(*)Lung cancer patients are followed up to 3 years post diagnosis only
(a) Estimates from Frontier Economics for the Department of Health (2011)
(b) Risk-adjusted estimates from GLM model
(c)(d)(C)(D) Risk-adjusted estimates from the BM estimator
(e) Risk-adjusted estimates from Weibull models
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estimate patient-level costs with continuous censoring
time and deaths, and to decompose the effect of routes to
diagnosis on costs into the effect due to the intensity of re-
source use, i.e. patients consuming more resources per
unit of time, and the effect due to survival, i.e. patients liv-
ing longer and having more chances to access health re-
sources. Our estimates show a modest cost per additional
year of life saved in the 5 years following the diagnosis:
£6456 in colorectal, £1057 in breast, −£662 in prostate
(cost savings), and £819 in lung cancer (3 years only).
We also examined the potential effects of reducing the
share of diagnoses occurring after an EP to match the
average level in the top 20% of CCGs with the lowest
share as observed during 2010–2013. We estimate the
total impact of this policy target after 5 years is
£11,481,948 against 1863 years of life saved for Colorec-
tal, £847,750 against 889 years of life saved for breast, −
£943,434 (cost savings) against 1195 years of life saved
for prostate, and £609,938 against 1011 years of life
saved for lung cancer (after 3 years). These estimates
echo Abdel-Rahman et al. [15] study showing that
10,000 more patients would be alive at 5 years post-
diagnosis if survivals in England matched the best in
Europe.
Our findings have important policy implications. We
provide evidence that policy interventions aimed at
Fig. 2 Share of Total Cancer Diagnoses Occurring after an Emergency Presentation in CCGs, 2010–2013. Each bar represents a CCG. Dark blue = Best
performing 20% of CCGs; Light blue = Other CCGs
Table 3 Effects of decreasing the share of cancers diagnosed after an EP to match the average level achieved by the top 20% of
CCGs with the lowest share
Colorectal Breast Prostate Lung
Patients rerouted from EP to GP/TWW referral 1303 577 964 1714
Non converted cases 29,977 7436 6320 9236
Total Costs 1 year post diagnosis £9,696,503 -£18,260 -£2,608,444 -£441,712
Total Costs 5 year post diagnosis £11,481,948 £847,750 -£943,434 £609,938
Patients surviving up to 5 years post diagnosis 468 295 393 255
Years of Life saved up to 5 years post diagnosis 1863 889 1195 1011
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rerouting patients from EP to GP/TWW referral are
likely to have a modest net impact in terms of additional
costs for the NHS, while they are likely to result in large
benefits to the patients. In the short term (1 year post
diagnosis), rerouting patients’ diagnosis generates net
savings in breast, prostate, and lung cancer, as additional
costs due to non-conversions and improved survivals are
outweighed by reduced costs due to lower intensity of
resource use and pre-diagnosis costs. In the long term
(5 years post diagnosis), costs due to improved survival
increase and outweigh the initial savings. Prostate cancer
is the only cohort showing savings after 5 years. Health
policies aiming at reducing the number of diagnoses
occurring after EP should be supported by appropriate
resources to take care of a larger number of patients
surviving cancer in the long term.
Moreover, we found evidence that a largest impact on
costs is generated by non-conversion cases. As more pa-
tients are referred by GPs for suspected cancer, the con-
version rate is likely to fall with a negative impact on
costs. Therefore, clinical research on more effective and
less expensive diagnostic tests will be key in supporting
future policy interventions aiming at rerouting patients
away from EP and late diagnoses. This is especially evi-
dent in colorectal cancer patients for whom the costs of
colonoscopy testing are very high, and alternative diag-
nostic tools, such as CT colonography, can achieve large
cost savings [16].
Our finding supports recent policy initiatives such as
the National Awareness and Early Diagnosis Initiative
(NAEDI), the Be Clear on Cancer campaign, and “Improv-
ing Outcomes: A Strategy for Cancer” [17] that have been
successful in reducing the share of patients diagnosed via
EP from 24% in 2006 down to 20% in 2013 [18].
Existing evidence
A number of early studies investigated the effect of in-
creasing the number of early diagnoses on costs using
simulation modelling approaches [11, 19–22]. Our evi-
dence is in line with Hinde et al. (2015) and Frontier
Economics’ findings that increasing the number of early
diagnoses is associated with a substantial increment in
costs due to non-conversions and a small reduction in
costs due to less intensive treatments for patients with a
positive diagnosis. However, our evidence are not dir-
ectly comparable with previous studies, since the starting
point of our analysis is a shift in the distribution of the
route to diagnosis, rather than in the distribution of can-
cer staging at diagnosis. Moreover, our observational
study design presents a number of important differences
from studies based on simulation models. First, our data
allow for comparing resource use associated with differ-
ent pathways of care and routes to diagnosis, without
having to model patients’ transitions into different states
of the disease that are often unobservable. Second, our
analysis does not rely on evidence from clinical trials
and expert opinions from clinical advisors on the “typ-
ical” pathways of care for patients in different states of
the disease. On the one hand, our analysis does not
allow for detailed costing of the different services that
are likely to be accessed by patients, and for selecting
only those services that have a direct link with the can-
cer treatment. On the other hand, it does allow for the
inclusion of the costs of care generated by patients out-
side the typical pathway of care. Deviations from the
pathway might occur for many different reasons, such as
the patient’s personal circumstances (e.g. socioeconomic
deprivation or living alone), the organisation of the local
health services, and the medical practice at the treat-
ment hospital. Observations on deviations from the
typical pathways of care are key to determine EP costs,
since diagnoses after an EP are likely to be the result of
such deviations. Finally, our analysis allows for the
indirect costs of cancer, i.e. costs generated as a result of
the interactions between cancer and post and pre-
existing health conditions. For instance, a patient with
a chronic condition that normally can be managed in
primary care might need a higher level of care to
treat the same condition associated with cancer (i.e.,
multi-morbidity effect).
Study limitations
Our cost estimates are based on a number of assump-
tions. We assumed GP referral conversion rates equal to
conversion rates for TWW GP referrals as no data is
available on the former. We assumed average diagnostic
costs reported by other studies [11]. We considered pre-
diagnosis costs 1 year before the diagnosis. We assumed
that reducing the share of EP to the average share in the
best performing 20% of CCGs is an achievable target.
Each of the assumptions above is clearly listed in Tables 2
and 3, and their impact on estimated total costs can be
easily assessed by replacing them with different values.
Patients diagnosed after an EP might be more likely to
have fast growing and difficult to detect tumours as
compared with patients diagnosed after a GP referral
reducing the scope for changing the route to diagnosis
[23]. We are unable to provide direct control for this
potential confounding factor in our analysis. However,
we observe a large variation in the share of patients
detected after an EP across CCG geographical areas (Fig.
2), which we interpret as evidence that prevalence of fast
growing cancer is unlikely to be the main driver and
three is scope for reducing diagnostic delays.
Some patients who are diagnosed through an EP may
not present to healthcare prior to their emergency
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admission limiting the scope for detection in primary
care. We mitigated this problem by estimating the
potential impact of matching the share of EP diagnoses
observed in a large number of best performing CCG.
This analysis assumed that there were no inherent
differences in the propensity for patients to seek care in
primary practice versus present as emergencies to
secondary care. We did control for patients’ characteris-
tics that are likely to increase the risk of diagnosis after
EP, such as age, gender, deprivation, and chronic health
conditions.
We considered five-year survival as the only health
outcome in this study. However, some cancers suffer
from lead-time bias, i.e. earlier diagnosis of disease
might not necessarily improve outcomes, and survival
does not always correspond to regression or cure of the
tumour. Additionally, many cancers found through
earlier diagnosis may be over diagnosed and would never
have had any detrimental impact on patient’s health,
thereby biasing estimated survivals. We mitigate such
limitations by excluding patients with non-malignant
tumours and excluding patients with history of malig-
nant tumours.
Some of the tests performed on non-converted cases
might lead to diagnosis for a different condition. Colon-
oscopy might detect an adenoma and potentially redu-
cing longer term cancer risk. Therefore, part of the non-
conversion costs might produce benefits that are not
taken into account in our analysis. Nor does such ana-
lysis acknowledge the potential psychological impact on
patients of increasing diagnostics for cancer.
Our study presents other limitations. Firstly, the ana-
lysis does not include the costs of primary care and so-
cial care. However, existing evidence shows that primary
care absorbs a small share of total cancer costs, about
3% of total costs [24], while only a small share of pa-
tients use social care services after their diagnosis, 15%
of lung, 13% of colorectal and 5% of breast and prostate
cancer patients [25]. Secondly, the quality of cost infor-
mation varies across hospitals and over time. To miti-
gate variation, we used costs at a fixed point in time
(2010), excluded outliers, and calculated costs of similar
services reported by different hospitals. Finally, the
routes to diagnosis are identified using the algorithm
formulated by Elliss-Brookes et al. [1] and related
assumptions. In particular, for emergency presentation,
all hospital activity in the 6 months pre-diagnosis was
assumed to be due to the cancer; other authors consider
a shorter cut-off point of 1 month [5].
Conclusion
Policies aimed at increasing the proportion of patients
diagnosed through primary care referral in colorectal,
lung, breast and prostate cancer are likely to be cost-
effective. Additional resources might be needed to sup-
port patients surviving longer after diagnosis. Improving
the national rates in line with those achieved by the
highest performing CCGs would result in a significant
increase in diagnostic tests for suspected cancer and as-
sociated costs.
Additional file
Additional file 1: Technical Appendix. Description of the Basu-Manning
estimator used in the statistical analysis. (DOCX 23 kb)
Acknowledgements
The data used for this research were extracted by the National Cancer
Registration and Analysis Service of Public Health England (PHE). We are
thankful to Sean McPhail, Lucy Irvine, and James Charnock at PHE for
support and advice in using the data. This work was supported by Macmillan
Cancer Support (Grant number: 4644727). The views expressed are those of
the authors and not necessarily of PHE nor Macmillan.
Funding
This work was funded by Macmillan Cancer Support (grant award number:
4644727). The funder had no active role in any stage of the study, including:
design, data collection, analysis, interpretation, and writing.
Availability of data and materials
The data that support the findings of this study are available from PHE, but
restrictions apply to the availability of these data, which were used
under license for the current study, and so are not publicly available.
Data are however available from the authors upon reasonable request
and with permission of PHE.
Authors’ contributions
The study was conceived and designed by ML. BW and PL conducted the
empirical analysis. BW and ML wrote the first draft. ML, BW, PL, EB, PCS
critically revised the first draft and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the NHS Health Research Authority – London
Stanmore Research Ethics Committee. Ref: 16/LO/2086. The study did not
involve data collection from animals or human participants. The study used
fully anonymized secondary data from the Cancer Registry of England. Public
Health England (PHE) is authorized to collect the data and is the data
custodian. PHE gave consent for the anonymized data used in this study.
Ref: ODR_1617_024.
Consent for publication
Not Applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1School of Health Sciences, City, University of London, EC1V 0HB, London,
UK. 2Social Research Division, Economic and Social Research Institute, Dublin
D02 K138, Ireland. 3Department of Surgery and Cancer, Imperial College
London, St Mary’s Campus, London W2 1NY, UK. 4Economics Department,
University of Palermo, Viale delle Scienze, 90128 Palermo, Italy. 5Business
School, Imperial College London, South Kensington Campus, London SW7
2AZ, UK.
Laudicella et al. BMC Cancer  (2018) 18:394 Page 8 of 9
Received: 14 September 2017 Accepted: 21 March 2018
References
1. Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S, et al.
Routes to diagnosis for cancer - determining the patient journey using
multiple routine data sets. Br J Cancer. 2012;107:1220–6.
2. McPhail S, Elliss-Brookes L, Shelton J, Ives A, Greenslade M, Vernon S, et al.
Emergency presentation of cancer and short-term mortality. Br J Cancer.
2013;109:2027–34.
3. Sheringham JR, Georghiou T, Chitnis XA, Bardsley M. Comparing primary
and secondary health-care use between diagnostic routes before a
colorectal cancer diagnosis: Cohort study using linked data. Br J Cancer.
2014;111:1490–9.
4. NCIN. Routes to diagnosis 2006–2013 preliminary results short report
[internet]. 2015. Available from: http://www.ncin.org.uk/publications/routes_
to_diagnosis
5. Tsang C, Bottle A, Majeed A, Aylin P. Cancer diagnosed by emergency
admission in England: An observational study using the general practice
research database. BMC Health Serv Res. 2013;13:308.
6. Rubin G, McPhail S, Elliott K. National Audit of Cancer diagnosis in primary
care. London: Royal College of General Practitioners; 2011. [cited 2016 May
5]; Available from: http://www.rcgp.org.uk/news/2011/november/~/media/
Files/News/National_Audit_of_Cancer_Diagnosis_in_Primary-Care.ashx
7. Renzi C, Lyratzopoulos G, Card T, Chu TPC, Macleod U, Rachet B. Do
colorectal cancer patients diagnosed as an emergency differ from non-
emergency patients in their consultation patterns and symptoms? A
longitudinal data-linkage study in England. Br J Cancer. 2016;115:866–75.
8. National Institute for Health and Care Excellence. Suspected cancer:
Recognition and referral [internet]. 2015 [cited 2015 Jul 24]. Available from:
http://www.nice.org.uk/guidance/ng12/evidence/full-guidance-65700685
9. Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in
England: Evidence from population-based patient-level data. Br J Cancer.
2016; [cited 2016 Apr 13]; Available from: http://www.nature.com/doifinder/
10.1038/bjc.2016.77
10. Thorn JC, Turner EL, Hounsome L, Walsh E, Down L, Verne J, et al. Validating
the use of hospital episode statistics data and comparison of costing
methodologies for economic evaluation: An end-of-life case study from the
cluster randomised triAl of PSA testing for prostate cancer (CAP). BMJ Open.
2016;6:e011063.
11. DH & Frontier Economics. The likely impact of earlier diagnosis of cancer on
costs and benefits to the NHS. 2011.
12. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs
related to cancer treatment from SEER-Medicare data. Med Care. 2002;
40:IV–104.
13. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al.
Cost of Care for Elderly Cancer Patients in the United States. J Natl Cancer
Inst. 2008;100:630–41.
14. Basu A, Manning WG. Estimating lifetime or episode-of-illness costs under
censoring. Health Econ. 2010;19:1010–28.
15. Abdel-Rahman M, Stockton D, Rachet B, Hakulinen T, Coleman MP. What if
cancer survival in Britain were the same as in Europe: How many deaths are
avoidable? Br J Cancer. 2009;101:S115–24.
16. Atkin W, Dadswell E, Wooldrage K, Kralj-Hans I, von Wagner C, Edwards R, et
al. Computed tomographic colonography versus colonoscopy for
investigation of patients with symptoms suggestive of colorectal cancer
(SIGGAR): A multicentre randomised trial. Lancet. 2013;381:1194–202.
17. Department of Health. Improving outcomes: A strategy for Cancer [internet].
2011 [cited 2015 Feb 10]. Available from: https://www.gov.uk/government/
uploads/system/uploads/attachment_data/file/213785/dh_123394.pdf
18. PHE. Cancers are being diagnosed earlier in England - press releases - GOV.
UK [internet]. 2015 [cited 2016 Jul 26]. Available from: https://www.gov.uk/
government/news/cancers-are-being-diagnosed-earlier-in-england
19. Hinde S, McKenna C, Whyte S, Peake MD, Callister MEJ, Rogers T, et al.
Modelling the cost-effectiveness of public awareness campaigns for the
early detection of non-small-cell lung cancer. Br J Cancer. 2015;113:135–41.
20. Incisive Health. Saving lives averting costs: An analysis of the financial
implications of achieving earlier diagnosis of colorectal, lung and ovarian
cancer - a report prepared for Cancer Research UK [internet]. 2014 [cited
2015 Feb 27]. Available from: http://www.incisivehealth.com/uploads/
Saving%20lives%20averting%20costs.pdf
21. Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J, et al.
Estimating the direct costs of bowel cancer services provided by the National
Health Service in England. Int J Technol Assess Health Care. 2010;26:362–9.
22. Pilgrim H, Tappenden P, Chilcott J, Bending M, Trueman P, Shorthouse A, et
al. The costs and benefits of bowel cancer service developments using
discrete event simulation. J Oper Res Soc. 2009;60:1305–14.
23. Neal RD. Do diagnostic delays in cancer matter? Br J Cancer. 2009;101:S9–12.
24. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer
across the European Union: A population-based cost analysis. Lancet Oncol.
2013;14:1165–74.
25. Nuffield Trust. Use of health and social care by people with cancer. 2014.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Laudicella et al. BMC Cancer  (2018) 18:394 Page 9 of 9
